PLAC1 and neoplasm: Exploring the targeting of PLAC1 to enhance NK cell-mediated anti-tumor responses could lead to the development of new immunotherapies that increase NK cell cytotoxicity or harness PLAC1’s immunogenic potential to improve cancer treatment outcomes.